Interstitial lung involvement in rheumatoid arthritis patients treated with abatacept: a prospective observational study

Key Points

• This study aims to evaluate the effect of interstitial lung disease on the retention rate of abatacept in rheumatoid arthritis patients.
• Prospective observational design
• Assessment of drug retention rates
• Evaluation of interstitial lung disease presence
• The presence of interstitial lung disease did not affect the retention rate of abatacept.
• Abatacept remains a viable treatment option for rheumatoid arthritis-related interstitial lung disease.